Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

Raziel Therapeutics, a Pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market announces licensing of its disruptive technology, RZL-012, to Fosun Pharma for milestone